Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
5 clinical trials · Condition
◉ Watch Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
| Record | Firm | Date |
|---|---|---|
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL (NCT05370430) | PeproMene Bio, Inc. | 2022-06-13 |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (NCT04028440) | Institute of Hematology & Blood Diseases Hospital, China | 2019-10-01 |
| MB-CART20.1 Lymphoma (NCT03664635) | Miltenyi Biomedicine GmbH | 2018-09-25 |
| Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation (NCT03456726) | Eisai Co., Ltd. | 2018-04-09 |
| A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NCT03009344) | Eisai Co., Ltd. | 2017-01-10 |
Track Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.